Fact CheckerSign in

NCT07573371Recruiting

Understanding and Tailored Treatment of Low Anterior Resection Syndrome

Source: ClinicalTrials.gov · Last updated 7 May 2026

Brief summary (registry, in English)

The goal of this observational study is to learn why some patients develop low anterior resection syndrome (LARS) after colorectal cancer treatment. The study also aims to identify different subtypes of LARS and understand which patients may respond to specific treatments. The main questions it aims to answer are: * What physiological and imaging changes are associated with LARS? * How do patients with LARS differ from patients without LARS after colorectal cancer surgery? * Are there measurable differences between LARS, patients treated with organ-preserving chemoradiotherapy, and patients with fecal incontinence? Participants will: * Complete advanced physiological and imaging assessments related to bowel function * Be compared with four control groups: * patients without LARS after colorectal cancer surgery * patients treated with organ-preserving chemoradiotherapy * patients with fecal incontinence and urge fecal incontinence * Take part in a single study visit where all measurements are performed

Status (registry)
Recruiting
Study type
Observational
Enrollment
145 (estimated)
First submitted
20 Apr 2026
Start date
17 Sept 2024
Primary completion date
31 Dec 2026
Lead sponsor
Aalborg University Hospital
NCT number
NCT07573371

What you commit to

  • Study type: Observational
  • Planned participants: 145
  • From 17 Sept 2024 to the primary completion date, 31 Dec 2026
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Participation in concomitant clinical trial

Other illness

  • Connective tissue disorders
  • Parkinson's disease
  • Allergic to latex
  • Known intestinal obstruction, significant intestinal strictures or perforation. If in doubt about intestinal stricture, the patient will be examined with MRI of the small intestine, colonoscopy or other supplementing examination
  • Disorders of swallowing
  • History of anastomotic leakage following rectal resection and sphincter preserving therapy
  • Evidens of local recurrence or dessimination of the cancer

Other

  • General exclusion criteria
  • Persons that are not able to understand information
  • Non-MRI compatible pacemaker, clips or other metal objects in the body. Patients implanted with a pacemaker for sacral nerve modulation will not undergo MRI postoperatively.
  • Piercings that cannot be removed before MRI
  • Claustrophobia
  • Abdominal diameter equal or more than 140 cm
  • Have other individual factors, in the opinion of the physician/healthcare professional, in which participating is contraindicated
  • Pregnant women
    • Specific exclusion criterias for LARS patients

Who the study is looking for

  • General:
  • Must be able to read and understand Danish.
  • All participants must be adults and \>18 years and have full legal capacity.
  • Assessed by study personnel to have understood the research protocol, being able to comply with investigation procedures as well as ability to come to the hospital at the agreed timepoints, and to complete the trial.
    • Specific inclusion criteria for LARS patients:
  • Patients operated for rectal cancer with a rectal resection and sphincter preserving surgery at a minimum of three months postop.
  • If patients have received a temporary protective ileostomy, this should have been reversed for a minimum of three months postop.
    • Specific inclusion criteria for fecal incontinence patients and urge fecal incontinence patients
  • Patients planned for neuromodulation.
  • Satisfactory interoperative test results leading to permanent implantation of a pacemaker for sacral nerve modulation.
    • Specific inclusion criteria for "watch and wait" patients:
  • Rectum/colon cancer patients treated with organ-preserving treatment, i.e., chemotherapy and radiotherapy with a complete clinical and radiological response at a minimum of 12 months posttreatment.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Aalborg University Hospital
Coordinator of this site? Confirm its status
AalborgDenmarkActive, not recruiting
Aarhus University Hospital
Coordinator of this site? Confirm its status
AarhusDenmarkRecruiting
Vejle Hospital
Coordinator of this site? Confirm its status
VejleDenmarkRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.